Researchers, healthcare providers and global health officials who worked hard to grapple with the devastating Ebola outbreak of West Africa between 2014 and 2016 can finally breathe a sigh of relief — the very first Ebola vaccine was finally approved in Europe. Known as Ervebo, this Ebola vaccine is manufactured by the biopharmaceutical company Merck and was granted marketing authorization by the European Commission on November 11. Prof. Gary Whittaker, virology, shared his insight on the inner workings of the vaccine and its development, as well as what this landmark achievement means for the future of global health. Whittaker explained that the vaccine itself is actually a recombinant virus, based on the backbone of vesicular stomatitis virus originating from sheep and goats. “[VSV] is very efficiently growing and relatively easy to make, [so] it’s engineered to express the glycoprotein of Ebola … it generates the immune response against the Ebola virus glycoprotein, which is equivalent to the surface protein of Ebola,” Whittaker said.